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Abstract
Background. A number of genomic conditions caused by copy number variants (CNVs) are
associated with a high risk of neurodevelopmental and psychiatric disorders (ND-CNVs).
Although these patients also tend to have cognitive impairments, few studies have investigated
the range of emotion and behaviour problems in young people with ND-CNVs using mea-
sures that are suitable for those with learning difficulties.
Methods. A total of 322 young people with 13 ND-CNVs across eight loci (mean age: 9.79
years, range: 6.02–17.91, 66.5% male) took part in the study. Primary carers completed the
Developmental Behaviour Checklist (DBC).
Results. Of the total, 69% of individuals with an ND-CNV screened positive for clinically sig-
nificant difficulties. Young people from families with higher incomes (OR = 0.71, CI = 0.55–
0.91, p = .008) were less likely to screen positive. The rate of difficulties differed depending on
ND-CNV genotype (χ2 = 39.99, p < 0.001), with the lowest rate in young people with 22q11.2
deletion (45.7%) and the highest in those with 1q21.1 deletion (93.8%). Specific patterns of
strengths and weaknesses were found for different ND-CNV genotypes. However, ND-
CNV genotype explained no more than 9–16% of the variance, depending on DBC
subdomain.
Conclusions. Emotion and behaviour problems are common in young people with ND-
CNVs. The ND-CNV specific patterns we find can provide a basis for more tailored support.
More research is needed to better understand the variation in emotion and behaviour pro-
blems not accounted for by genotype.
Introduction
Many copy number variants (CNVs), caused by reciprocal deletions and duplications of
chromosomal regions such as 1q21.1, 16p11.2 or 22q11.2, are associated with the development
of neurodevelopmental disorders (hereafter referred to as ND-CNVs) (Chawner et al., 2019;
Torres, Barbosa, & Maciel, 2015). These ND-CNVs are associated with a broad psychiatric
and physical phenotype, often with variable expressivity and incomplete penetrance. This
means that while some individuals with ND-CNVs are affected by many complex physical
and mental health symptoms, others may display few or none (Crawford et al., 2018). As
the technology used to detect these changes continues to improve, the rate of diagnosis of
ND-CNVs is increasing. Therefore, there is a need to advance our understanding of the clin-
ical outcomes associated with these genetic conditions. This will allow clinicians to provide
optimal counselling and intervention to patients and families.
There is abundant evidence that individuals with ND-CNVs have higher rates of neurode-
velopmental and psychiatric disorders than the general population (Bernier et al., 2016;
Chawner et al., 2019; Glassford, Rosenfeld, Freedman, Zwick, & Mulle, 2016; Hanson et al.,
2014; Schneider et al., 2014; Vermeulen et al., 2017). In addition to this, in individuals with
ND-CNVs some disorders may show patterns of symptoms that differ from the classical pres-
entation. For example, in individuals with 22q11.2DS, attention deficit-hyperactivity disorder
is often of the inattentive subtype, rather than the hyperactive or combined subtypes that are
more common in children without the deletion (Niarchou, Martin, Thapar, Owen, & van den
Bree, 2015). In addition to these differences, there are often complex patterns of co-occurring
symptoms, both physical and psychological, with evidence suggesting that there is an increased
risk of psychiatric disorders in children with ND-CNVs who also display motor coordination
problems (Cunningham et al., 2018), a history of seizures (Eaton et al., 2019), or sleep distur-
bances (Moulding et al., 2019). ID is common in individuals with ND-CNVs but can range
from mild to severe (Chawner et al., 2019; Hanson et al., 2014; Schneider et al., 2014;
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Vissers, Gilissen, & Veltman, 2016), with evidence that the IQ of
family members explains part of this vulnerability (Hanson et al.,
2014).
Assessing mental health status in individuals with ID can be
difficult (Matson & Shoemaker, 2011). Research studies often
use standardized assessments of psychiatric disorder that follow
the DSM or ICD classification systems. While these assessments
allow for common discourse between researchers, they may not
adequately assess disorders that present differently or are easily
confused with symptoms of ID (Costello & Bouras, 2006).
This difficulty in assessing mental health status in individuals
with ID has implications for studies investigating psychopath-
ology associated with ND-CNVs, as participants are likely to
have some degree of cognitive impairment. Despite this, few stud-
ies have used assessments of psychopathology that are tailored for
individuals with ID (Einfeld, Tonge, & Florio, 1997; Vermeulen
et al., 2017; Wagner, Niemczyk, Equit, Curfs, & von Gontard,
2017). Thus, behaviours that are more common in individuals
with ID will not have been captured. The Developmental
Behaviour Checklist (DBC) (Einfeld & Tonge, 1995) is designed
to measure emotional and behavioural problems in young people
with ID. Using the DBC in studies of individuals with ND-CNVs
can, therefore, provide important insights into ID-specific beha-
viours that may have been missed in previous research.
In addition to this, few studies have conducted cross-CNV
comparisons of emotion and behaviour problems in young people
with ND-CNVs (Di Nuovo & Buono, 2011; Vermeulen et al.,
2017). It is, therefore, unclear if there are differences in the sever-
ity of specific behaviours or emotional difficulties between indi-
vidual ND-CNV genotypes. Knowing if these differences exist is
important as it will influence what counselling or support should
be provided.
To address the gaps in the literature surrounding emotion and
behaviour disturbance profiles in young people with ND-CNVs,
we assessed a sample of 322 young people with a range of 13
ND-CNVs, across eight loci, using the DBC (Einfeld & Tonge,
1995). We investigated the following questions: (1) What propor-
tion of young people with an ND-CNV screen positive for clinic-
ally significant emotion and behaviour disturbance as measured
using the DBC? (2) Are there differences in these disturbances
between males and females with ND-CNVs? (3) Do health and
pregnancy-related variables influence rates of clinically significant
difficulties? (4) Which emotion and behaviour problems are par-
ticularly elevated in young people with ND-CNVs? (5) Are there
differences between ND-CNV genotypes in risk for the presence
of clinically significant difficulties?
Methods
Participants
A total of 322 participants with ND-CNVs (including one of
15q11.2 deletion, 15q13.3 deletion, 15q13.3 duplication, 16p11.2
deletion, 16p11.2 distal deletion, 16p11.2 duplication, 1q21.1 dele-
tion, 1q21 duplication, 22q11.2 deletion, 22q11.2 duplication,
9q34.3 deletion (Kleefstra syndrome), NRXN1 (2p16.3 deletion)
or TAR (1q21.1) duplication (66.5% male, mean age: 9.79 years,
range: 6.02–17.91) assessed between September 2011 and
November 2018 as part of the ECHO and IMAGINE-ID studies
at Cardiff University. Participants were recruited on the basis of
having an ND-CNV of interest, not the presence of ID or other
neurodevelopmental disorder. Data from all instruments used
were collected at the same time. Families were recruited through
UK Medical Genetics clinics, word of mouth, and charities and
support groups for chromosomal disorders including Unique,
MaxAppeal! and 22qCrew. Informed and written consent was
obtained prior to recruitment from the carers of the children,
or the children themselves where appropriate. Recruitment was
carried out in agreement with protocols approved by the appro-
priate university and National Health Service (NHS) ethics and
research and development committees. Families were visited at
home for phenotyping including cognitive and psychiatric assess-
ments. ND-CNV genotypes were established from medical
records as well as in-house genotyping at the Cardiff University
MRC Centre for Neuropsychiatric Genetics and Genomics using
microarray analysis. Information about the pregnancy and the
children’s medical history, including congenital heart defects, his-
tory of epilepsy as well as psychiatric and epilepsy medication use
was collected through primary carer report. Psychiatric and epi-
lepsy medication use is listed in online Supplementary Table 1.
The developmental behaviour checklist
We used the DBC, which was developed to assess emotion and
behaviour problems in individuals with ID (Einfeld & Tonge,
1995). It has been used in studies of idiopathic ID (Einfeld
et al., 2006) as well as studies of genetic syndromes associated
with ID (Einfeld et al., 1997; Rice et al., 2016; Wagner et al.,
2017). The DBC provides total behaviour problems score
(TBPS) as well as scores on five subscales: disruptive/antisocial
behaviour (27 items), self-absorbed behaviour (30 items), social
relating (10 items), communication disturbance (13 items), and
anxiety (9 items). Some items are present in more than one
domain. Responses are coded as 0 = ‘not true’, 1 = ‘somewhat
true’, 2 = ‘certainly true’. See Fig. 1 for all items that are included
in each of these subscales. Two items, ‘masturbates or exposes self
in public’ and ‘inappropriate sexual behaviour with another’ were
not included in this study, because the research team deemed
these less appropriate to ask the primary carer to complete by
questionnaire. Thus, the DBC version we used included a total
of 94 items. The DBC can also be used to screen for the presence
of clinically significant emotion and behaviour difficulties, indi-
cated by a TBPS greater than 45.
Statistical analysis
Statistical analysis was carried out in R version 3.6.3
(Development Core Team, 2011). In total, 460/30 268 (1.5%) of
total DBC responses were missing. These were assumed to be
missing at random and imputed using k-nearest neighbour
imputation with k = 5 using the ‘VIM’ package to create a com-
plete dataset (Kowarik & Templ, 2016).
In order to address Aim 1, the percentage of individuals with
an ND-CNV displaying clinically significant emotion and behav-
ioural difficulties (TBPS >45) was calculated. As the presence of
clinically significant emotion and behavioural difficulties is a
dichotomous (yes/no) variable, we used logistic regression to
investigate if age, gender, approximate family income and mater-
nal education level were predictors of the presence of clinically
significant emotion or behavioural difficulties.
For aim 2, we used a chi-squared test to learn if rates of screen-
ing positive for clinically significant difficulties differed by gender.
We also used t tests to investigate if the continuous DBC total
problems score and subscale scores differed by gender.
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Fig. 1. Heat plots of scores for the items constituting the five subscales of the DBC (a) disruptive/antisocial, (b) communication disturbance (c ) self-absorbed (d)
social relating and (e) anxiety. Items are ordered on the x-axis by mean total severity score for each question across the entire ND-CNV sample, from lowest on the
left to highest on the right. The chart above each heat plot shows the mean total severity score and 95% confidence interval for each question. Point shape cor-
responds to the significance of results of a t test comparing the mean of the total severity score of the question to the overall mean for all items in the scale.
Squares indicate a nonsignificant difference, circles indicate a nominally significant difference and triangles indicate questions that survived Benjamini-
Hochberg correction.
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To address aim 3, we used logistic regression to investigate if
health and pregnancy-related variables were associated with the
presence or absence of clinically significant difficulties. We con-
structed models where the dichotomous variable ‘presence of clin-
ically significant difficulties’ was predicted by the presence of
congenital heart defects; a history of epileptic fits; being part of
multiple births; whether the mother had fertility treatment during
the pregnancy; or prolonged labour (longer than 36 h); the baby
having spent time in a special care baby unit (SCBU); or in an
incubator; or having been born prematurely (before 37 weeks
for a single birth, or before 34 weeks for twins). These variables
were included in addition to gender, age, maternal education
and approximate family income.
In order to address aim 4, we plotted heatmaps of all the items
comprising each DBC subdomain. This allowed us to investigate
which emotion and behaviour problems impact relatively more
or less severely on young people with ND-CNVs (Fig. 1a–e). In
these heatmaps, each cell represents the deviation from the
mean for each question and each ND-CNV genotype. For
example, for the disruptive/antisocial subscale (Fig. 1a) the aver-
age score for each of the 27 items was calculated for each of the 13
ND-CNV genotypes giving a total of 351 values. The mean of
these 351 values was calculated, and the deviation from the
mean for each ND-CNV and item combination was plotted.
Each cell, therefore, represents the deviation from the overall
mean of the 351 values in the plot. To compare between different
subscales (Fig. 1a–e) these deviations were linearly transformed to
fall between 1 and −1 when plotted. In addition, to establish
which items within each subscale are more or less common in
young people with ND-CNV, we conducted t tests comparing
the mean score across all ND-CNV groups for each item within
a subscale with the mean score of all other items included in a
subscale.
In order to address aim 5, we constructed a model with all cov-
ariates we found to be significant in the analysis of aims 1–3 (e.g.
income) and added ‘ND-CNV genotype’ as an additional factor.
We used a likelihood ratio test to establish if this additional factor
contributed significantly to variation in DBC TBPS.
Furthermore, we used ANCOVAs to test if the continuous
DBC-TBPS and scores on each of the five subscales differed by
ND-CNV genotype, again including those covariates we had
found to be predictors of the presence of clinically significant
behavioural difficulties in aim 1 and aim 2. The pattern of severity
across the TBPS and subscales was visualised (Fig. 1a–e) by plot-
ting the marginal mean TBPS and subscale score for each
ND-CNV genotype. These marginal means represent the pre-
dicted score after adjusting for those variables that were previously
found to be predictors of the presence of clinically significant
behavioural difficulties.
We also carried out ANCOVAs to investigate if the type of
ND-CNV (deletion or duplication) or ND-CNV inheritance sta-
tus (inherited from parent or de novo), were associated with
TBPS, or scores on each of the five subscales. The association
between inheritance status and ND-CNV genotype was tested
with a chi-squared test of independence.
In order to test whether there are differences in the severity
with which the different ND-CNVs impact on TBPS and the
five subscales, we used Friedman’s chi-square test. In addition,
to test the concordance between scores on the scales, we used
Kendall’s F-test. Kendall’s F test also provides a coefficient of con-
cordance W. The coefficient of concordance allows us to assess
the level of agreement in scores across ND-CNV genotypes. W
can take values between 0 and 1, with 0 indicating no agreement
in scores, and 1 indicating perfect agreement (Salkind, 2010). It
can be interpreted as an effect size, with 0.1⩾ 0.3 corresponding
to a small effect, 0.3⩾ 0.5 a moderate effect, and >0.5 a large
effect.
The procedures outlined for aim 3 and aim 5 were repeated
excluding those individuals who were taking psychiatric or epi-
lepsy medication to establish if this would change the findings.
For all analyses conducted, we checked to ensure they met
assumption requirements.
To correct for multiple testing across the analyses, we applied a
Benjamini–Hochberg correction of p values (Benjamini &
Hochberg, 1995) using the p.adjust function in R, and report
both original and adjusted p values throughout the Results
section.
Results
Table 1 describes the participants who took part in the study.
Participants were aged from 6.01 to 17.91 years (mean age =
9.79) and 33.5% were female.
A high percentage of young people with ND-CNVs screen
positive for clinically significant difficulties on the DBC and
family income plays a role
In total, 223 of 322 (69.3%) individuals with an ND-CNV
screened positive for clinically significant difficulties. Logistic
regression showed this was predicted by family income (OR =
0.71, CI = 0.55–0.91, p = 0.008, padj = 0.025) with children from
families with higher incomes being less likely to experience clin-
ically significant difficulties. Age, gender and maternal education
level were not associated with the presence of clinically significant
difficulties.
No gender differences
A chi-squared test revealed that there was no difference between
the number of males (156/214, 72.9%) or females (67/108,
62.0%) that screened positive for clinically significant difficulties
(χ2 = 3.48, p = 0.062, padj = 0.131). However, we found a nomin-
ally significant difference in self-absorbed score, with males scor-
ing higher than females (t = 2.10, p = 0.037, padj = 0.083). Mean
total problems score, or mean scores on any other subscale did
not differ between males and females.
Health and pregnancy-related variables are not associated
with rates of clinically significant difficulties in young people
with ND-CNVs
We examined the influence of the following variables on the pres-
ence of clinically significant difficulties: the presence of congenital
heart defects; a history of epileptic fits; being part of a multiple
births; whether the mother had fertility treatment during the
pregnancy; or prolonged labour (>36 h); the baby having spent
time in a special care baby unit (SCBU); or in an incubator; or
having been born prematurely (before 37 weeks for a single
birth, or before 34 weeks for twins). The model also included
age, gender, maternal education level and approximate family
income as covariates. None of these health or pregnancy-related
variables was associated with screening positive or negative for
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Table 1. Descriptive and summary statistics for the sample of children with neurodevelopmental copy number variants. Variables described are A) family background, B) demographics, C) Cognition, D) Developmental Behaviour
Checklist scores and E) Health related variables.
15q11.2
deletion
(N = 36)
15q13.3
deletion
(N = 20)
15q13.3
duplication
(N = 10)
16p11.2
deletion
(N = 52)
16p11.2 distal
deletion
(N = 13)
16p11.2
duplication
(N = 23)
1q21.1
deletion
(N = 16)
1q21.1
duplication
(N = 21)
22q11.2
deletion
(N = 70)
22q11.2
duplication
(N = 23)
Kleefstra
syndrome
(N = 12)
NRXN1
(N = 16)
TAR duplication
(N = 10)
Total
(N = 322)
(A) Family background
Maternal education
N-Miss 0 0 0 0 0 1 0 0 1 1 0 0 0 3
Low (O-levels, GCSE’s) 8 (22.2%) 7 (35.0%) 2 (20.0%) 18 (34.6%) 6 (46.2%) 4 (18.2%) 3 (18.8%) 5 (23.8%) 14 (20.3%) 3 (13.6%) 2 (16.7%) 7 (43.8%) 0 (0.0%) 79 (24.8%)
Middle (A-level’s,
Highers, vocational training)
14 (38.9%) 5 (25.0%) 5 (50.0%) 17 (32.7%) 4 (30.8%) 8 (36.4%) 6 (37.5%) 12 (57.1%) 31 (44.9%) 10 (45.5%) 5 (41.7%) 4 (25.0%) 6 (60.0%) 127
(39.8%)
High (University/
postgraduate degree)
9 (25.0%) 7 (35.0%) 3 (30.0%) 12 (23.1%) 3 (23.1%) 7 (31.8%) 4 (25.0%) 2 (9.5%) 20 (29.0%) 7 (31.8%) 5 (41.7%) 5 (31.2%) 2 (20.0%) 86 (27.0%)
No School Leaving
Exams
5 (13.9%) 1 (5.0%) 0 (0.0%) 5 (9.6%) 0 (0.0%) 3 (13.6%) 3 (18.8%) 2 (9.5%) 4 (5.8%) 2 (9.1%) 0 (0.0%) 0 (0.0%) 2 (20.0%) 27 (8.5%)
Approximate family income
N-Miss 4 1 1 10 1 3 2 1 7 2 1 2 0 35
< = £ 19 999 9 (28.1%) 4 (21.1%) 4 (44.4%) 14 (33.3%) 3 (25.0%) 10 (50.0%) 5 (35.7%) 12 (60.0%) 14 (22.2%) 8 (38.1%) 5 (45.5%) 3 (21.4%) 4 (40.0%) 95 (33.1%)
£ 20 000 - £ 39 999 11 (34.4%) 7 (36.8%) 2 (22.2%) 15 (35.7%) 6 (50.0%) 7 (35.0%) 8 (57.1%) 3 (15.0%) 14 (22.2%) 5 (23.8%) 1 (9.1%) 9 (64.3%) 6 (60.0%) 94 (32.8%)
£ 40 000 - £ 59 999 9 (28.1%) 3 (15.8%) 3 (33.3%) 10 (23.8%) 1 (8.3%) 2 (10.0%) 0 (0.0%) 3 (15.0%) 16 (25.4%) 6 (28.6%) 2 (18.2%) 2 (14.3%) 0 (0.0%) 57 (19.9%)
£ 60 000 + 3 (9.4%) 5 (26.3%) 0 (0.0%) 3 (7.1%) 2 (16.7%) 1 (5.0%) 1 (7.1%) 2 (10.0%) 19 (30.2%) 2 (9.5%) 3 (27.3%) 0 (0.0%) 0 (0.0%) 41 (14.3%)
(B) Demographics of child participants
Child ethnicity
N-Miss 0 0 1 0 0 0 0 0 0 1 0 0 0 2
European 33 (91.7%) 18 (90.0%) 9 (100.0%) 48 (92.3%) 13 (100.0%) 21 (91.3%) 15 (93.8%) 21 (100.0%) 64 (91.4%) 20 (90.9%) 11 (91.7%) 16
(100.0%)
10 (100.0%) 299
(93.4%)
Other 3 (8.3%) 2 (10.0%) 0 (0.0%) 4 (7.7%) 0 (0.0%) 2 (8.7%) 1 (6.2%) 0 (0.0%) 6 (8.6%) 2 (9.1%) 1 (8.3%) 0 (0.0%) 0 (0.0%) 21 (6.6%)
Age of child participants
N-Miss 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Mean (S.D.) 9.495
(3.018)
9.747
(3.123)
9.010 (2.840) 9.826
(3.256)
10.022 (3.298) 10.576 (3.480) 9.664
(2.781)
9.233 (3.377) 9.891
(2.863)
9.761 (3.240) 12.191 (3.911) 8.892
(2.773)
8.831 (2.590) 9.794
(3.119)
Range 6.022–
16.380
6.169–
15.419
6.413–15.186 6.068–
17.477
6.135–16.750 6.197–17.280 6.079–
15.829
6.016–17.060 6.019–
17.905
6.297–16.480 6.255–17.577 6.160–
15.667
6.594–14.092 6.016–
17.905
Gender of child participants
N-Miss 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Female 8 (22.2%) 3 (15.0%) 2 (20.0%) 19 (36.5%) 4 (30.8%) 9 (39.1%) 6 (37.5%) 11 (52.4%) 27 (38.6%) 6 (26.1%) 7 (58.3%) 2 (12.5%) 4 (40.0%) 108
(33.5%)
Male 28 (77.8%) 17 (85.0%) 8 (80.0%) 33 (63.5%) 9 (69.2%) 14 (60.9%) 10 (62.5%) 10 (47.6%) 43 (61.4%) 17 (73.9%) 5 (41.7%) 14 (87.5%) 6 (60.0%)
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Table 1. (Continued.)
15q11.2
deletion
(N = 36)
15q13.3
deletion
(N = 20)
15q13.3
duplication
(N = 10)
16p11.2
deletion
(N = 52)
16p11.2 distal
deletion
(N = 13)
16p11.2
duplication
(N = 23)
1q21.1
deletion
(N = 16)
1q21.1
duplication
(N = 21)
22q11.2
deletion
(N = 70)
22q11.2
duplication
(N = 23)
Kleefstra
syndrome
(N = 12)
NRXN1
(N = 16)
TAR duplication
(N = 10)
Total
(N = 322)
214
(66.5%)
ND-CNV Inheritance status
N-Miss 19 (52.8%) 12 (60.0%) 5 (50.0%) 36 (69.2%) 11 (84.6%) 17 (73.9%) 10 (62.5%) 14 (66.7%) 14 (20.0%) 12 (52.2%) 8 (66.7%) 9 (56.2%) 6 (60.0%) 173
(53.7%)
De Novo 1 (2.8%) 1 (5.0%) 1 (10.0%) 12 (23.1%) 2 (15.4%) 1 (4.3%) 0 (0.0%) 1 (4.8%) 51 (72.9%) 1 (4.3%) 4 (33.3%) 4 (25.0%) 0 (0.0%) 79 (24.5%)
Inherited 16 (44.4%) 7 (35.0%) 4 (40.0%) 4 (7.7%) 0 (0.0%) 5 (21.7%) 6 (37.5%) 6 (28.6%) 5 (7.1%) 10 (43.5%) 0 (0.0%) 3 (18.8%) 4 (40.0%) 70 (21.7%)
(C ) Cognition
Full-scale IQ
N-Miss 8 2 1 4 1 2 1 0 9 2 5 4 2 41
Mean (S.D.) 80.964
(11.983)
73.389
(12.971)
91.667 (19.545) 76.542
(11.265)
81.667
(12.666)
79.381 (12.742) 78.200
(11.143)
86.286
(17.559)
74.902
(10.957)
86.476 (17.102) 60.143
(13.031)
80.417
(16.665)
82.000 (13.586) 78.811
(14.077)
Range 53.000–
103.000
55.000–
102.000
55.000–
116.000
56.000–
116.000
60.000–
103.000
53.000–101.000 63.000–
105.000
53.000–
128.000
54.000–
100.000
56.000–
114.000
50.000–80.000 65.000–
127.000
66.000–107.000 50.000–
128.000
Performance IQ
N-Miss 6 2 1 3 1 2 1 0 8 2 3 5 2 36
Mean (S.D.) 87.600
(13.992)
77.889
(12.778)
96.889 (18.537) 84.796
(11.923)
82.000
(11.878)
82.000 (10.950) 80.200
(9.221)
90.810
(16.482)
76.774
(10.659)
90.524 (20.707) 62.889
(12.036)
85.636
(17.408)
87.000 (14.031) 83.000
(14.695)
Range 57.000–
124.000
56.000–
106.000
62.000–
115.000
63.000–
119.000
64.000–
104.000
58.000–102.000 69.000–
103.000
58.000–
126.000
57.000–
106.000
57.000–
127.000
53.000–84.000 69.000–
132.000
72.000–111.000 53.000–
132.000
Verbal IQ
N-Miss 7 1 1 4 1 2 1 0 9 2 5 3 2 38
Mean (S.D.) 77.586
(11.425)
72.789
(12.809)
87.778 (17.448) 72.375
(12.006)
84.250
(12.664)
80.429 (17.066) 80.800
(15.599)
84.238
(17.490)
77.098
(12.416)
84.905 (13.707) 61.857
(11.725)
77.615
(15.441)
80.250 (13.833) 77.986
(14.354)
Range 55.000–
103.000
55.000–
101.000
55.000–
113.000
55.000–
110.000
63.000–
101.000
55.000–107.000 60.000–
120.000
55.000–
123.000
55.000–
100.000
62.000–
112.000
55.000–80.000 58.000–
117.000
64.000–101.000 55.000–
123.000
(D) Developmental behaviour checklist
Total behavioural problems score
N-Miss 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Mean (S.D.) 80.111
(29.871)
71.300
(26.160)
72.400 (41.762) 51.115
(24.463)
67.846
(26.655)
78.087 (27.624) 72.625
(31.256)
69.952
(21.388)
44.286
(26.107)
64.652 (32.109) 67.500
(21.000)
71.750
(19.485)
56.300 (28.414) 62.450
(29.622)
Range 16.000–
130.000
27.000–
125.000
17.000–
139.000
2.000–
102.000
34.000–
108.000
17.000–121.000 13.000–
157.000
19.000–
108.000
4.000–
115.000
10.000–
121.000
31.000–99.000 32.000–
105.000
9.000–94.000 2.000–
157.000
Disruptive/antisocial subscale
N-Miss 0 0 0 0 0 0 0 0 0 0 0 0 0 0
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Mean (S.D.) 26.083
(13.622)
23.400
(10.995)
26.500 (15.953) 15.635
(8.682)
23.769
(11.300)
29.087 (12.007) 27.000
(11.989)
21.429 (9.442) 14.929
(10.220)
21.609 (12.752) 19.000 (9.420) 23.375
(9.598)
17.300 (9.934) 20.689
(11.901)
Range 7.000–
49.000
8.000–
43.000
3.000–47.000 1.000–
38.000
12.000–44.000 4.000–48.000 5.000–
53.000
6.000–39.000 1.000–
42.000
2.000–45.000 6.000–33.000 9.000–
47.000
2.000–30.000 1.000–
53.000
Self-absorbed subscale
N-Miss 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Mean (S.D.) 25.139
(11.248)
23.200
(10.390)
23.300 (16.042) 15.712
(9.456)
20.769 (8.946) 24.087 (10.867) 22.500
(11.564)
22.571
(10.225)
12.843
(9.165)
21.435 (11.599) 25.500 (7.116) 25.125
(8.563)
16.900 (10.300) 19.708
(11.123)
Range 6.000–
51.000
3.000–
47.000
3.000–54.000 0.000–
35.000
9.000–35.000 1.000–41.000 0.000–
50.000
3.000–41.000 1.000–
37.000
6.000–48.000 15.000–36.000 11.000–
41.000
0.000–33.000 0.000–
54.000
Communication disturbance subscale
N-Miss 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Mean (S.D.) 11.556
(4.398)
10.300
(4.473)
10.800 (5.653) 7.635
(3.881)
10.077 (6.184) 10.478 (4.450) 9.188
(6.014)
10.048 (3.775) 6.514
(4.089)
9.174 (6.322) 12.250 (4.224) 10.625
(4.440)
9.100 (5.626) 9.106
(4.907)
Range 1.000–
21.000
2.000–
18.000
1.000–19.000 0.000–
16.000
1.000–18.000 1.000–18.000 0.000–
24.000
2.000–16.000 0.000–
17.000
0.000–21.000 3.000–17.000 1.000–
18.000
0.000–19.000 0.000–
24.000
Anxiety subscale
N-Miss 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Mean (S.D.) 9.611
(4.544)
7.450
(4.298)
6.100 (4.306) 6.558
(3.765)
6.077 (3.904) 8.826 (3.099) 7.562
(3.898)
7.619 (3.853) 5.886
(4.221)
6.870 (4.192) 5.333 (4.008) 7.125
(4.161)
8.300 (4.620) 7.115
(4.187)
Range 0.000–
17.000
0.000–
16.000
1.000–14.000 0.000–
16.000
0.000–13.000 3.000–14.000 1.000–
15.000
1.000–15.000 0.000–
18.000
0.000–13.000 1.000–13.000 0.000–
14.000
0.000–14.000 0.000–
18.000
Social relating subscale
N-Miss 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Mean (S.D.) 7.722
(3.677)
6.950
(3.379)
5.700 (3.860) 5.577
(4.336)
7.154 (4.543) 5.609 (3.115) 6.375
(4.129)
8.286 (3.452) 4.114
(3.573)
5.565 (3.203) 5.417 (3.029) 5.500
(2.921)
4.700 (2.111) 5.832
(3.806)
Range 0.000–
15.000
0.000–
12.000
0.000–12.000 0.000–
15.000
0.000–15.000 0.000–11.000 1.000–
15.000
2.000–14.000 0.000–
16.000
0.000–11.000 1.000–10.000 0.000–
13.000
1.000–8.000 0.000–
16.000
(E) Health-Related variables
Participants taking psychiatric or epilepsy medication
N-Miss 0 0 0 0 0 0 0 0 0 0 0 0 0 0
No 30 (83.3%) 19 (95.0%) 9 (90.0%) 45 (86.5%) 12 (92.3%) 17 (73.9%) 14 (87.5%) 19 (90.5%) 67 (95.7%) 20 (87.0%) 11 (91.7%) 13 (81.2%) 10 (100.0%) 286
(88.8%)
Yes 6 (16.7%) 1 (5.0%) 1 (10.0%) 7 (13.5%) 1 (7.7%) 6 (26.1%) 2 (12.5%) 2 (9.5%) 3 (4.3%) 3 (13.0%) 1 (8.3%) 3 (18.8%) 0 (0.0%) 36 (11.2%)
Congenital heart problems
N-Miss 0 0 0 2 0 1 0 2 0 1 0 0 2 8
No 33 (91.7%) 18 (90.0%) 9 (90.0%) 45 (90.0%) 12 (92.3%) 19 (86.4%) 14 (87.5%) 15 (78.9%) 37 (52.9%) 17 (77.3%) 8 (66.7%) 13 (81.2%) 7 (87.5%)
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Table 1. (Continued.)
15q11.2
deletion
(N = 36)
15q13.3
deletion
(N = 20)
15q13.3
duplication
(N = 10)
16p11.2
deletion
(N = 52)
16p11.2 distal
deletion
(N = 13)
16p11.2
duplication
(N = 23)
1q21.1
deletion
(N = 16)
1q21.1
duplication
(N = 21)
22q11.2
deletion
(N = 70)
22q11.2
duplication
(N = 23)
Kleefstra
syndrome
(N = 12)
NRXN1
(N = 16)
TAR duplication
(N = 10)
Total
(N = 322)
247
(78.7%)
Yes 3 (8.3%) 2 (10.0%) 1 (10.0%) 5 (10.0%) 1 (7.7%) 3 (13.6%) 2 (12.5%) 4 (21.1%) 33 (47.1%) 5 (22.7%) 4 (33.3%) 3 (18.8%) 1 (12.5%) 67 (21.3%)
History of epileptic fits
N-Miss 0 0 0 2 0 0 0 1 1 0 1 0 0 5
No 25 (69.4%) 18 (90.0%) 10 (100.0%) 36 (72.0%) 12 (92.3%) 23 (100.0%) 14 (87.5%) 15 (75.0%) 56 (81.2%) 21 (91.3%) 11 (100.0%) 10 (62.5%) 9 (90.0%) 260
(82.0%)
Yes 11 (30.6%) 2 (10.0%) 0 (0.0%) 14 (28.0%) 1 (7.7%) 0 (0.0%) 2 (12.5%) 5 (25.0%) 13 (18.8%) 2 (8.7%) 0 (0.0%) 6 (37.5%) 1 (10.0%) 57 (18.0%)
Born prematurely (<37 Weeks)
N-Miss 2 2 1 2 0 4 1 3 4 0 0 0 2 21
Early 16 (47.1%) 9 (50.0%) 5 (55.6%) 22 (44.0%) 6 (46.2%) 9 (47.4%) 12 (80.0%) 7 (38.9%) 34 (51.5%) 11 (47.8%) 5 (41.7%) 9 (56.2%) 4 (50.0%) 149
(49.5%)
Not Early 18 (52.9%) 9 (50.0%) 4 (44.4%) 28 (56.0%) 7 (53.8%) 10 (52.6%) 3 (20.0%) 11 (61.1%) 32 (48.5%) 12 (52.2%) 7 (58.3%) 7 (43.8%) 4 (50.0%) 152
(50.5%)
Child part of multiple birth
N-Miss 1 1 0 2 0 2 2 4 2 0 0 0 0 14
No 34 (97.1%) 19 (100.0%) 10 (100.0%) 49 (98.0%) 13 (100.0%) 21 (100.0%) 14 (100.0%) 16 (94.1%) 66 (97.1%) 23 (100.0%) 12 (100.0%) 15 (93.8%) 10 (100.0%) 302
(98.1%)
Yes 1 (2.9%) 0 (0.0%) 0 (0.0%) 1 (2.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (5.9%) 2 (2.9%) 0 (0.0%) 0 (0.0%) 1 (6.2%) 0 (0.0%) 6 (1.9%)
Fertility treatment used during pregnancy
N-Miss 2 2 0 5 0 2 2 4 2 0 0 0 0 19
No 30 (88.2%) 17 (94.4%) 10 (100.0%) 42 (89.4%) 13 (100.0%) 21 (100.0%) 13 (92.9%) 17 (100.0%) 65 (95.6%) 22 (95.7%) 11 (91.7%) 15 (93.8%) 10 (100.0%) 286
(94.4%)
Yes 4 (11.8%) 1 (5.6%) 0 (0.0%) 5 (10.6%) 0 (0.0%) 0 (0.0%) 1 (7.1%) 0 (0.0%) 3 (4.4%) 1 (4.3%) 1 (8.3%) 1 (6.2%) 0 (0.0%) 17 (5.6%)
Prolonged labour
N-Miss 3 3 1 3 1 3 2 4 3 0 0 0 0 23
No 27 (81.8%) 15 (88.2%) 9 (100.0%) 44 (89.8%) 12 (100.0%) 16 (80.0%) 12 (85.7%) 14 (82.4%) 59 (88.1%) 20 (87.0%) 11 (91.7%) 14 (87.5%) 8 (80.0%) 261
(87.3%)
Yes 6 (18.2%) 2 (11.8%) 0 (0.0%) 5 (10.2%) 0 (0.0%) 4 (20.0%) 2 (14.3%) 3 (17.6%) 8 (11.9%) 3 (13.0%) 1 (8.3%) 2 (12.5%) 2 (20.0%) 38 (12.7%)
Birth by caesarean section
N-Miss 1 1 1 2 0 2 3 4 2 1 0 0 0 17
No 23 (65.7%) 16 (84.2%) 8 (88.9%) 31 (62.0%) 8 (61.5%) 15 (71.4%) 10 (76.9%) 8 (47.1%) 49 (72.1%) 12 (54.5%) 9 (75.0%) 12 (75.0%) 9 (90.0%) 210
(68.9%)
Yes 12 (34.3%) 3 (15.8%) 1 (11.1%) 19 (38.0%) 5 (38.5%) 6 (28.6%) 3 (23.1%) 9 (52.9%) 19 (27.9%) 10 (45.5%) 3 (25.0%) 4 (25.0%) 1 (10.0%) 95 (31.1%)
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clinically significant difficulties. This remained the case after
excluding individuals taking psychiatric or epilepsy medication.
ID-associated emotions and behaviours that are more or less
common in young people with ND-CNVs
In order to investigate which emotions and behaviours are more
or less common in individuals with ND-CNVs, we plotted the
deviation from the mean for each item and each ND-CNV geno-
type in a heatmap (Fig. 1). For each subscale, the mean total
severity scores for each question were calculated and then ranked
from lowest to highest. The items with the highest mean severity
scores were ‘easily led by others’ on the disruptive/antisocial scale,
‘doesn’t mix well with own age group’ on the communication dis-
turbance scale, ‘poor sense of danger’ on the self-absorbed scale,
‘tends to be a loner’ on the social relating scale and ‘fears particu-
lar things or situations’ on the anxiety scale. The lowest mean
severity scores were seen for ‘lights fires’ on the disruptive/anti-
social scale, ‘overly interested in mechanical things’ on the com-
munication disturbance scale, ‘bites others’ on the self-absorbed
scale, ‘Sleeps too much’ on the social relating scale, and ‘loss of
appetite’ on the anxiety scale. Full results are shown in Fig. 1.
Questions that remained significant after correction for multiple
comparisons are indicated by red points in each upper panel.
ND-CNV genotypes differ in risk for clinically significant
difficulties on the DBC
To investigate if ND-CNV genotypes differ in risk for clinically
significant difficulties (based on total DBC cut-off), we performed
a likelihood ratio test comparing models where the presence of
difficulties was predicted by family income with a model where
ND-CNV genotype was also included. The addition of
ND-CNV genotype improved prediction of the presence of clin-
ically significant difficulties (df = 12, χ2 = 39.99, p = <0.001, padj-
<0.001). Figure 2. shows the percentage of individuals
displaying clinically significant difficulties by ND-CNV genotype.
Rates of clinically significant difficulties differed across genotypes
(χ2 = 51.20, df = 12, p < 0.001, padj = <0.001). Rates of screening
positive ranged from 45.7% (32/70) in 22q11.2 deletion to
93.8% (15/16) in individuals with 1q21.1 deletion. ND-CNV
genotype remained a significant predictor after excluding indivi-
duals taking psychiatric or epilepsy medication (df = 12, χ2 =
36.58, p < 0.001, padj = 0.001).
ND-CNV genotype was associated with TBPS and all subscales
(Table 2). Table 2 also presents the variance in the TBPS and sub-
domain scores that is explained by ND-CNV genotype (final col-
umn, ηp
2). This was found to range from 9.3% for anxiety to 15.9%
of the self-absorbed score, along with genotype explaining 16.4%
of the variance in TBPS. There remained a significant effect of
ND-CNV genotype for all scores when individuals taking psychi-
atric or epilepsy medication were excluded.
We also used ANCOVAs to investigate if having an inherited
(n = 79) or de novo (n = 70) ND-CNV (173 individuals had
unknown inheritance) or if the type of genomic change (deletion
or duplication) affected TBPS or subscale scores, with family
income as a covariate. These tests revealed that having an
inherited ND-CNV was associated with greater TBPS (F = 7.46,
df = 1, p = 0.007, padj = 0.022, ηp
2 = 0.053), disruptive/antisocial
score (F = 4.64, p = 0.033, padj = 0.075, ηp
2 = 0.034), self-absorbed
score (F = 4.69, df = 1, p = 0.032, padj = 0.074, ηp
2 = 0.034), commu-
nication disturbance score (F = 9.20, df = 1, p = 0.003, padj = 0.011,
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ηp
2 = 0.065) and anxiety score (F = 5.11, df = 1, p = 0.025, padj =
0.059, ηp
2 = 0.037) but not social relating score. However, inherit-
ance was also strongly associated with ND-CNV genotype (χ2 =
90.85, df = 12, Cramer’s V = 0.781, p = <0.001, padj<0.001), and
including both ND-CNV genotype and inheritance status in the
model resulted in inheritance no longer being significantly asso-
ciated with greater problems. Type of genomic change was not
associated with TBPS or scores on any of the subscales.
The patterns of severity across DBC subdomains between the
ND-CNV genotypes can be seen in Fig. 3, which plots marginal
mean scores on the TBPS and each of the subscales. These mar-
ginal mean scores represent the predicted score after adjusting for
family income. Using a Friedman’s Chi-squared test, we found
that there was a significant difference in the severity of scores
depending on ND-CNV genotype (Friedman χ2 = 40.09, df = 12,
p < 0.001, padj<0.001). Kendall’s coefficient of concordance
revealed that there was also high concordance between scores
on the subscales (F = 6.28, p < 0.001, padj<0.001) with a large effect
size (W = 0.56).
Discussion
This is the first study, as far as we are aware, that compares phe-
notypes between a range of different ND-CNV genotypes using a
measure of emotion and behaviour problems designed for young
people with ID. We demonstrate that emotion and behaviour dif-
ficulties are highly prevalent across the ND-CNV genotypes we
studied, with 69.3% of young people with ND-CNVs screening
positive for clinically significant difficulties. ND-CNV genotype
was associated with both screening positive for clinically signifi-
cant difficulties, as well as total behaviour problems score
(TBPS), suggesting that the ND-CNV genotypes display different
levels and patterns of difficulties. We found that ND-CNV geno-
type explained approximately 16.4% of the variance in TBPS and
between 7 and 16% of the variance in subscale scores. Type of
genomic change (deletion or duplication), did not affect DBC
scores. Our models suggested that children with inherited
ND-CNVs did display greater overall difficulties, and greater
levels of disruptive/antisocial problems, self-absorbed behaviours,
communication disturbance, and anxiety problems than children
with de novo variants. However, inheritance status and ND-CNV
genotype were significantly linked, reflecting that rates of inherit-
ance differed between ND-CNV genotypes. We were therefore not
able to evaluate the impact of inheritance status independently.
Fig. 2. Percentages of individuals screening positive and
negative for clinically significant difficulties (DBC total
problems score >45).
Table 2. Variance explained by ND-CNV genotype on (A) DBC total problems
score, and (B–F) subscale scores, with family income as a covariate
(A) DBC total problems F p padj ηp
2
ND-CNV 4.45 <0.001 <0.001 0.164
Family Income 1.09 0.352 0.454 0.012
(B) Disruptive/antisocial
ND-CNV 3.85 <0.001 <0.001 0.146
Family Income 1.05 0.371 0.472 0.011
(C) Communication
disturbance
ND-CNV 3.08 <0.001 <0.001 0.120
Family Income 0.64 0.591 0.643 0.007
(D) Self-absorbed
ND-CNV 4.28 <0.001 <0.001 0.159
Family Income 1.17 0.322 0.430 0.013
(E) Social relating
ND-CNV 3.09 <0.001 <0.001 0.120
Family Income 1.01 0.388 0.484 0.011
(F) Anxiety
ND-CNV 2.32 0.008 0.024 0.093
Family Income 0.67 0.571 0.628 0.007
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Previous studies have described high rates and complex pre-
sentations of psychiatric and neurodevelopmental difficulties in
individuals with ND-CNVs (Chawner et al., 2019; Niarchou
et al., 2014; Schneider et al., 2014; Steinman et al., 2016) using
standard psychiatric assessments. Our findings, using a measure
designed for use in ID that focuses on emotion and behaviour dis-
turbance, offers further evidence for elevated rates of psychopath-
ology in individuals with ND-CNVs.
We found no evidence of gender differences in the rate of clin-
ically significant difficulties. This agrees with previous research
using the DBC in populations with intellectual disability (Einfeld
& Tonge, 1996; Koskentausta & Almqvist, 2004). However, we
did find that screening positive for emotion and behaviour pro-
blems was associated with family income, suggesting that a higher
income might be protective against problems with emotion and
behaviour in young people with ND-CNVs. It will be important
to further explore the mechanisms underlying this protective effect.
Within the ND-CNV sample we found that scores on aggres-
sive and problematic conduct behaviour such as ‘lights fires’, ‘bites
others’, ‘steals’ were consistently lowered compared to the average,
while questions that might indicate difficulties with socialising
such as ‘doesn’t mix with own age group’, ‘poor sense of danger’
or ‘tends to be a loner’; along with questions related to mood and
attention, such as ‘cries easily’, ‘becomes overexcited’, ‘has temper
tantrums’, ‘impatient’ or ‘impulsive’ were consistently found to be
more severe than the average. This might suggest that broadly
speaking, children with ND-CNVs show fewer problems with
aggressive behaviour or conduct problems, but may need extra
support around socialising and mood problems alongside atten-
tion and hyperactivity symptoms.
In the present study, we also find differences in both screening
positive for difficulties and in severity scores depending on
ND-CNV genotype. Rates of positive screening for clinically sig-
nificant difficulties ranged from 45.7% in young people with
22q11.2 deletion to 93.8% in young people with 1q21.1 deletion.
The implication of this is that some ND-CNV genotypes are more
likely to display problems with emotion and behaviour than
others. This is also supported by our findings of high concordance
Fig. 3. Marginal mean scores for each ND-CNV genotype on (a) DBC total problems score and (b–f) the five subscales. The overall group mean and 1 standard
deviation above and below are indicated by the dashed lines. Error bars indicate 95% confidence intervals of the estimated marginal mean. Marginal means
are estimated from ANCOVAs including family income as a covariate.
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of severity scores for the ND-CNV genotypes between the DBC
scales, which suggests that those ND-CNVs that score low on
one scale also score low on the other scales, and vice versa.
However, ND-CNV genotype explained only a low proportion
of variance in TBPS and subscale severity scores. This suggests
that there are other factors that contribute to psychopathology
in these individuals. These could include background genetic
risk (potentially measured by a polygenic risk score) (Cleynen
et al., 2019) and environmental risk factors, such as bullying or
lack of family support. Indeed, we find that approximate family
income is predictive of rates of clinically significant difficulties,
in agreement with evidence that lower socioeconomic status is
associated with greater rates of childhood multimorbidity
(Cornish, Boyd, Van Staa, Salisbury, & Macleod, 2013; Johnson,
Cornish, Boyd, & Macleod, 2019).
This is the largest study of its kind to investigate patterns of
emotion and behaviour problems across different ND-CNV gen-
otypes. However, there are differences in the size of samples of
individuals with different ND-CNV genotypes. We were also
unable to account for familial liability for behavioural problems
as the DBC is not suited for assessments in unaffected familial
members, who are unlikely to display ID. While we found poten-
tial evidence that individuals with inherited ND-CNVs displayed
greater difficulties, this was confounded by the strong association
between inheritance and ND-CNV genotype. We can therefore
not draw any conclusions about the effect of inheritance on
behavioural problems.
Ascertainment bias may affect our results, as the developmen-
tal delay is a major reason for referral for genetic testing in the
UK. This might be highlighted by our findings of individuals
with 15q11.2 deletion having some of the most severe scores on
the DBC, despite continued debate over the clinical significance
of this ND-CNV genotype (Butler, 2017), along with the relatively
lower problems displayed by individuals with 22q11.2 deletion,
who are more likely to be referred to genetics clinics for medical
issues. It may be that the full range of outcomes (including no or
mild phenotypic effects) are not captured in this study. However,
even if we are predominantly including those who are also more
likely to have a higher load of background genetic and environ-
mental risk factors, it is still important to better understand the
difficulties faced by this group of patients, as they make up a sig-
nificant proportion of those presenting for clinical genetic testing
and care following a CNV diagnosis.
Clinicians such as genetic counsellors or paediatricians often
lack complete information on the likely outcomes of patients
with an ND-CNV in their care and are therefore unable to pro-
vide accurate counselling or advice to patients or their families.
Improving our knowledge and understanding of emotion and
behaviour risk is, therefore, key to improving counselling provi-
sion and access to appropriate services. This is particularly rele-
vant as numbers of patients presenting for genetic screening
will increase as the technology used to detect chromosomal aber-
rations continues to improve.
Clinical implications
Immediate clinical implications of these findings should be
increased vigilance for emotion and behaviour problems in indi-
viduals with ND-CNVs. If ID is suspected, then psychiatric
assessments that are designed to be used in individuals with ID
should be applied. Particular difficulties in individuals with
ND-CNVs may be poor social skills, attention difficulties and
mood problems. However, it would be best for every child to com-
plete a DBC so that interventions can be targeted at an individual
level. In addition, patients who display both ID and emotion or
behaviour problems, in the absence of any physical injury that
could cause ID, are potential candidates for genetic screening
for contributory genetic variants. Individuals from lower-income
backgrounds may be at greater risk for clinically significant diffi-
culties with emotions and behaviour.
Conclusions
Emotion and behaviour difficulties are common in individuals
with ND-CNVs. These problems may show specific patterns
depending on ND-CNV genotype, but individuals with
ND-CNVs show particular problems with social relating, atten-
tion, impulsivity and fearing particular things or situations. It is
important that future research involving young people with
ND-CNVs includes measures adapted for ID such as the DBC.
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